Rachel M. Abbott
Milton Park
Abingdon, ENG, United Kingdom
Abingdon, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer.
Journal: Cancer discovery
Published: February 02, 2024
Enhancing Efficacy of TCR-engineered CD4 + T Cells Via Coexpression of CD8α.
Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)
Published: October 25, 2022
Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: December 02, 2020
Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+ T cell recognition across all three phases of the lytic cycle.
Journal: PLoS pathogens
Published: January 23, 2014
CD8+ T cell responses to lytic EBV infection: late antigen specificities as subdominant components of the total response.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: October 23, 2013
Investigating the structure of the factor B vWF-A domain/CD55 protein-protein complex using DEER spectroscopy: successes and pitfalls.
Journal: Molecular physics
Published: April 15, 2013
MHC II tetramers visualize human CD4+ T cell responses to Epstein-Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 response.
Journal: The Journal of experimental medicine
Published: April 10, 2013
Expansion of somatically reverted memory CD8+ T cells in patients with X-linked lymphoproliferative disease caused by selective pressure from Epstein-Barr virus.
Journal: The Journal of experimental medicine
Published: April 12, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026